Schedule

This session will showcase the latest advances in experimental platforms that reduce reliance on animal testing while improving human relevance. Speakers will highlight innovative organoid models, microphysiological systems (MPS), and in chemico approaches that offer mechanistic insight and translational value in human disease research. Ellen Shrock, University of Washington Antibody Immunodominance is Germline-Encoded Carolina Gonzalez, Scripps College Advancing Drug Repositioning with Explainable Graph Neural Networks Shehzad Z. Sheikh, University of North Carolina at Chapel Hill

Dr. Thaddeus Shug, NIHThe Complement Animal Research In Experimentation (Complement-ARIE) Program application requirements for the NAMs Technology Development Centers funding opportunity, and a Q&A session during which NIH staff will answer questions from the audience

This session explores how artificial intelligence, machine learning, and in silico modeling are transforming health prediction and chemical risk assessment. Talks will focus on leveraging AI for drug repurposing, simulating complex biological systems, and integrating large datasets to refine predictive frameworks like Adverse Outcome Pathways. James Glazier, Indiana University Bloomington Use of digital twins to model the immune response or infectious disease process Weida Tong, NCTR/FDA From Animals to Algorithms: AI in DILI Risk Evaluation Camilla Dos Santos, Cold Spring Harbor Laboratory Understanding Molecular Mechanisms of Breast Cancer using Human Mammary Organoids